NO954457L - Oksygenredusert vandig opplösning av faktor VIII - Google Patents

Oksygenredusert vandig opplösning av faktor VIII

Info

Publication number
NO954457L
NO954457L NO954457A NO954457A NO954457L NO 954457 L NO954457 L NO 954457L NO 954457 A NO954457 A NO 954457A NO 954457 A NO954457 A NO 954457A NO 954457 L NO954457 L NO 954457L
Authority
NO
Norway
Prior art keywords
factor viii
aqueous solution
pct
oxygen
present
Prior art date
Application number
NO954457A
Other languages
English (en)
Other versions
NO321769B1 (no
NO954457D0 (no
Inventor
Thomas Osterberg
Angelica Fatouros
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO954457D0 publication Critical patent/NO954457D0/no
Publication of NO954457L publication Critical patent/NO954457L/no
Publication of NO321769B1 publication Critical patent/NO321769B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19954457A 1993-05-07 1995-11-07 Oksygenredusert vandig opplosning av faktor VIII og fremgangsmate for fremstilling av denne. NO321769B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation
PCT/SE1994/000265 WO1994026286A1 (en) 1993-05-07 1994-03-24 Oxygen-reduced aqueous solution of factor viii

Publications (3)

Publication Number Publication Date
NO954457D0 NO954457D0 (no) 1995-11-07
NO954457L true NO954457L (no) 1995-11-07
NO321769B1 NO321769B1 (no) 2006-07-03

Family

ID=20389868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19954457A NO321769B1 (no) 1993-05-07 1995-11-07 Oksygenredusert vandig opplosning av faktor VIII og fremgangsmate for fremstilling av denne.

Country Status (24)

Country Link
US (1) US5962650A (no)
EP (1) EP0700299B1 (no)
JP (1) JP3751633B2 (no)
KR (1) KR100304143B1 (no)
CN (1) CN1113655C (no)
AT (1) ATE218354T1 (no)
AU (1) AU681883B2 (no)
CA (1) CA2161350C (no)
CZ (1) CZ293527B6 (no)
DE (1) DE69430745T2 (no)
DK (1) DK0700299T3 (no)
EE (1) EE03118B1 (no)
ES (1) ES2177579T3 (no)
FI (1) FI111910B (no)
HU (1) HU215263B (no)
NO (1) NO321769B1 (no)
NZ (1) NZ266031A (no)
PL (1) PL174866B1 (no)
PT (1) PT700299E (no)
RU (1) RU2142290C1 (no)
SE (1) SE9301581D0 (no)
SK (1) SK283002B6 (no)
WO (1) WO1994026286A1 (no)
ZA (1) ZA942251B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP5149470B2 (ja) * 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
DK1194161T3 (da) * 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
JP3466516B2 (ja) 1999-09-07 2003-11-10 科学技術振興事業団 安定保存可能な酸素輸液剤
BR0215216A (pt) * 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
CA2470313A1 (en) * 2001-12-21 2003-07-10 Michael Bech Jensen Liquid composition of modified factor vii polypeptides
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
KR20150138427A (ko) 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
ATE471158T1 (de) * 2007-04-17 2010-07-15 Schwabe Willmar Gmbh & Co Verfahren zur herstellung von lagerstabilen lösungen aus pelargonium-extrakten
US8399620B2 (en) * 2007-07-11 2013-03-19 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
ES2382443T3 (es) * 2008-09-03 2012-06-08 Octapharma Ag Composiciones estabilizadas para factor VIII producido de manera recombinante
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
ES2966234T3 (es) * 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US9005343B2 (en) 2010-05-05 2015-04-14 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
JP5930483B2 (ja) 2010-08-25 2016-06-08 ニュー・ヘルス・サイエンシーズ・インコーポレイテッドＮｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 保存中の赤血球の品質及び生存を高める方法
EP3539381B1 (en) 2010-11-05 2023-05-24 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
MX347503B (es) 2010-11-05 2017-04-26 Baxalta Inc Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US9877476B2 (en) 2013-02-28 2018-01-30 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
CN107530377B (zh) 2015-03-10 2021-09-03 新健康科学股份有限公司 氧减少一次性套件、装置及其使用方法
KR102661405B1 (ko) 2015-04-23 2024-04-25 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
CN107735095B (zh) 2015-05-18 2022-06-14 希玛奈克斯特股份有限公司 储存全血的方法及其组合物
AU2017271545C1 (en) 2016-05-27 2023-06-15 Hemanext Inc. Anaerobic blood storage and pathogen inactivation method
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2896381A (en) * 1954-05-27 1959-07-28 Hodes Lange Corp Method and apparatus for treating and filling ampoules
US3143471A (en) * 1962-01-18 1964-08-04 Merck & Co Inc Argon method of drying and preserving lyophilized therapeutic products
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0212040B1 (de) * 1985-08-05 1990-05-23 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
US4709819A (en) * 1986-07-23 1987-12-01 Environmental Diagnostics, Inc. Method for preserving plated media and product
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
EP0789612B1 (en) * 1994-10-31 2002-09-04 Kimberly-Clark Worldwide, Inc. High density nonwoven filter media

Also Published As

Publication number Publication date
HU215263B (hu) 1998-11-30
DK0700299T3 (da) 2002-09-23
CA2161350C (en) 2007-10-30
SE9301581D0 (sv) 1993-05-07
ZA942251B (en) 1994-11-01
PT700299E (pt) 2002-11-29
AU681883B2 (en) 1997-09-11
US5962650A (en) 1999-10-05
EP0700299B1 (en) 2002-06-05
HU9503171D0 (en) 1996-01-29
CN1122573A (zh) 1996-05-15
NO321769B1 (no) 2006-07-03
DE69430745D1 (de) 2002-07-11
CZ286995A3 (en) 1996-05-15
ATE218354T1 (de) 2002-06-15
PL311567A1 (en) 1996-02-19
FI955305A0 (fi) 1995-11-06
NO954457D0 (no) 1995-11-07
RU2142290C1 (ru) 1999-12-10
SK283002B6 (sk) 2003-01-09
FI955305A (fi) 1995-11-06
DE69430745T2 (de) 2002-10-17
JPH08509745A (ja) 1996-10-15
FI111910B (fi) 2003-10-15
PL174866B1 (pl) 1998-09-30
CN1113655C (zh) 2003-07-09
CZ293527B6 (cs) 2004-05-12
CA2161350A1 (en) 1994-11-24
JP3751633B2 (ja) 2006-03-01
HUT73693A (en) 1996-09-30
AU6659794A (en) 1994-12-12
NZ266031A (en) 1997-04-24
ES2177579T3 (es) 2002-12-16
EE03118B1 (et) 1998-10-15
WO1994026286A1 (en) 1994-11-24
KR100304143B1 (ko) 2001-11-22
SK138395A3 (en) 1997-02-05
KR960702317A (ko) 1996-04-27
EP0700299A1 (en) 1996-03-13

Similar Documents

Publication Publication Date Title
NO954457D0 (no) Oksygenredusert vandig opplösning av faktor VIII
BR9607922A (pt) Produto medicamentoso final de uma proteína de plasma processos para preparar o produto medicamentoso final para melhorar a estabilidade de longo prazo de uma proteína de plasma e para tratar hemofilia e uso de um produto medicamentoso final
CA1158551A (en) Plasminogen preparations
DE69019084D1 (de) Methoden zur Verhinderung von Schimmel.
ATE73671T1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
PL320342A1 (en) Thrombin inhibitor containing infusion solution, stable during storage
ATE130761T1 (de) Stabiles mittel auf hämoglobinbasis und verfahren zu dessen einlagerung.
SE9402119D0 (sv) Solution
Zilva The antiscorbutic fraction of lemon juice. V
ATE66147T1 (de) Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
SI0662513T1 (en) Methods for preventing degradation of protein C
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees